Mumby, Sharon
Perros, Frederic
Grynblat, Julien
Manaud, Gregoire
Papi, Alberto
Casolari, Paolo
Caramori, Gaetano
Humbert, Marc
John Wort, S.
Adcock, Ian M.
Funding for this research was provided by:
British Heart Foundation (PG/14/27/30679, PG/14/27/30679, PG/14/27/30679)
Article History
Received: 7 February 2023
Accepted: 23 July 2023
First Online: 29 July 2023
Declarations
:
: <i>Endothelial cells</i>Healthy HPMECs were purchased from Promocell GmbH (Heidelberg, Germany) and cultured according to the supplier’s instructions in Endothelial cell growth medium MV (Promocell GmbH).PAH endothelial cells: Lung parenchyma was collected at the time of lung transplantation from PAH patients, part of the French Network on Pulmonary Hypertension, a program approved by local Institutional Ethics Committee. All patients gave written informed consent (protocol N8CO-08-003, ID RCB:2008-A00485-50, approved June 2008).<i>Smooth muscle cells</i>For control PASMC, lung parenchyma was collected from control subjects at lobectomy or pneumonectomy for suspected lung tumour. The study protocol was approved by the BRU Biobank at the Royal Brompton Hospital and Ethical approval was obtained for the study (#10/H0504/9) and all donors gave consent for the use of their tissue.PAH-HPASMC: Lung parenchyma was collected at the time of lung transplantation from PAH patients, part of the French Network on Pulmonary Hypertension, a program approved by our Institutional Ethics Committee, and patients had given written informed consent (protocol N8CO-08–003, ID RCB:2008-A00485-50, approved June 2008).
: Not applicable.
: SM, FP, JG, GM, AP and PC—have no competing interests. IMA and GC—editorial Board members for Journal of Inflammation (London). SJW—declares consultation fees from Janssen, MSD and Acceleron and Research grant funding and other financial funding from Janssen. MH—declares financial funding to his Institution from Acceleron, AOP Orphan, Janssen, Merck and Shou Ti. Personal funding from Acceleron, Aerovate, Altavant, AOP Orphan, Bayer, Chiesi, Ferrer, Janssen, Merck, MorphogenIX and United Therapeutics. Honoraria from Janssen and Merck. Advisory board member for Acceleron, Altavant, Janssen, Merck and United Therapeutics.